转移性错配修复缺陷/微卫星不稳定结直肠癌患者免疫检查点阻断疗效预测
研究纳入116例微卫星不稳定转移性结直肠癌患者,采用高通量DNA和RNA测序,在NIPICOL II期试验(发现集)和ImmunoMSI前瞻性队列(验证集)中寻找免疫检查点抑制剂疗效预测标志物。结果显示既往提示耐药的DNA/RNA指标无影响,而涉及19个微卫星突变的多重MSI特征和182个RNA标志物(非上皮TGFB相关促纤维增生方向)可独立预测无进展生存。
要点
- 既往提示耐药的MSIsensor评分、肿瘤突变负荷等DNA/RNA指标未显示影响。
- 19个微卫星突变的多重MSI特征可预测iPFS(验证集HR=3.63)。
- 182个非上皮TGFB相关促纤维增生RNA标志物可独立预测iPFS(验证集HR=1.75)。
核心结论
- 微卫星不稳定转移性结直肠癌患者的iPFS可通过分析上皮肿瘤细胞中含微卫星的DNA基因突变状态联合非上皮TGFB相关促纤维增生RNA标志物来预测。
研究设计与样本
- 研究结合高通量DNA和RNA测序,分析116例接受抗PD-1±抗CTLA-4治疗的微卫星不稳定转移性结直肠癌患者的肿瘤样本,发现集为NIPICOL II期试验(C1,NCT03350126),验证集为ImmunoMSI前瞻性队列(C2)。
主要发现
- 在C1中与ICI疗效显著相关的DNA/RNA预测因子随后在C2中验证,主要终点为基于iRECIST的无进展生存期(iPFS)。
- 既往提示耐药的DNA/RNA指标(如MSIsensor评分、肿瘤突变负荷或特定细胞和分子肿瘤成分)未显示影响。
- iPFS取决于涉及19个微卫星突变的多重MSI特征(验证集HR=3.63;95%CI 1.65-7.99;P=1.4×10⁻³)。
- iPFS还取决于182个RNA标志物的表达,这些标志物具有非上皮TGFB相关促纤维增生方向(验证集HR=1.75;95%CI 1.03-2.98;P=0.035)。
- DNA和RNA特征均独立预测iPFS。
关键数值与推荐
- 多重MSI特征涉及19个微卫星突变,验证集HR=3.63(95%CI 1.65-7.99;P=1.4×10⁻³)。
- RNA标志物集包含182个标记,具有非上皮TGFB相关促纤维增生方向,验证集HR=1.75(95%CI 1.03-2.98;P=0.035)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mismatch repair-deficient (dMMR) tumors displaying microsatellite instability (MSI) represent a paradigm for the success of immune checkpoint inhibitor (ICI)-based immunotherapy, particularly in patients with metastatic colorectal cancer (mCRC). However, a proportion of patients with dMMR/MSI mCRC exhibit resistance to ICI. Identification of tools predicting MSI mCRC patient response to ICI is required for the design of future strategies further improving this therapy. PATIENTS AND METHODS: We combined high-throughput DNA and RNA sequencing of tumors from 116 patients with MSI mCRC treated with anti-programmed cell death protein 1 ± anti-cytotoxic T-lymphocyte-associated protein 4 of the NIPICOL phase II trial (C1, NCT03350126, discovery set) and the ImmunoMSI prospective cohort (C2, validation set). The DNA/RNA predictors whose status was significantly associated with ICI status of response in C1 were subsequently validated in C2. Primary endpoint was progression-free survival by immune RECIST (iRECIST) (iPFS). RESULTS: Analyses showed no impact of previously suggested DNA/RNA indicators of resistance to ICI, e.g. MSIsensor score, tumor mutational burden, or specific cellular and molecular tumoral contingents. By contrast, iPFS under ICI was shown in C1 and C2 to depend both on a multiplex MSI signature involving the mutations of 19 microsatellites hazard ratio cohort C2 (HRC2) = 3.63; 95% confidence interval (CI) 1.65-7.99; P = 1.4 × 10-3] and the expression of a set of 182 RNA markers with a non-epithelial transforming growth factor beta (TGFB)-related desmoplastic orientation (HRC2 = 1.75; 95% CI 1.03-2.98; P = 0.035). Both DNA and RNA signatures were independently predictive of iPFS. CONCLUSIONS: iPFS in patients with MSI mCRC can be predicted by simply analyzing the mutational status of DNA microsatellite-containing genes in epithelial tumor cells together with non-epithelial TGFB-related desmoplastic RNA markers.
引用
- Ratovomanana T, Nicolle R, Cohen R, et al. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2023. PMID: 37269904. doi:10.1016/j.annonc.2023.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。